Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses

BACKGROUND: Though currently approved immunotherapies, including chimeric antigen receptor T cells and checkpoint blockade antibodies, have been successfully used to treat hematological and some solid tumor cancers, many solid tumors remain resistant to these modes of treatment. In solid tumors, the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Brempelis, Katherine J, Cowan, Courtney M, Kreuser, Shannon A, Labadie, Kevin P, Prieskorn, Brooke M, Lieberman, Nicole A P, Ene, Chibawanye I, Moyes, Kara W, Chinn, Harrison, DeGolier, Kole R, Matsumoto, Lisa R, Daniel, Sara K, Yokoyama, Jason K, Davis, Amira D, Hoglund, Virginia J, Smythe, Kimberly S, Balcaitis, Stephanie D, Jensen, Michael C, Ellenbogen, Richard G, Campbell, Jean S, Pierce, Robert H, Holland, Eric C, Pillarisetty, Venu G, Crane, Courtney A
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Immune Cell Therapies and Immune Cell Engineering
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594542/
https://ncbi.nlm.nih.gov/pubmed/33115946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001356
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados